Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 411

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry

Terrier, Benjamin, Amoura, Zahir, Ravaud, Philippe, Hachulla, Eric, Jouenne, Romain, Combe, Bernard, Bonnet, Christine, Cacoub, Patrice, Cantagrel, Alain, De Bandt, Michel, Fain, Olivier, Fautrel, Bruno, Gaudin, Philippe, Godeau, Bertrand, Harlé, Jean‐Robert, Hot, Arnaud, Kahn, Jean‐Emmanuel, Lambotte, Olivier, Larroche, Claire, Léone, Jean, Meyer, Olivier, Pallot‐Prades, Béatrice, Pertuiset, Edouard, Quartier, Pierre, Schaerverbeke, Thierry, Sibilia, Jean, Somogyi, Alexandre, Soubrier, Martin, Vignon, Eric, Bader‐Meunier, Brigitte, Mariette, Xavier, Gottenberg, Jacques‐Eric·2010·Arthritis & Rheumatism

Abstract

Objective: A number of open‐label studies have suggested the potential benefit of rituximab (RTX) in systemic lupus erythematosus (SLE). However, in 2 recent randomized controlled trials (RCTs) of RTX, the primary end points were not met. We undertook this study to evaluate the safety and efficacy of RTX in off‐trial patients with SLE seen in regular clinical practice. Methods: We analyzed prospective data from the French AutoImmunity and Rituximab (AIR) registry, which includes data on patients with autoimmune disorders treated with RTX. Results: One hundred thirty‐six patients received treatment for SLE. The mean ± SD score on the Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the SLE Disease Activity Index (SLEDAI) was 11.3 ± 8.9 at baseline. Severe infections were noted in 12 patients (9%), corresponding to a rate of 6.6/100 patient‐years. Most severe infections occurred within the first 3 months after the last RTX infusion. Five patients died, due to severe infection (n = 3) or refractory autoimmune disease (n = 2). Overall response was observed in 80 of 113 patients (71%) by the SELENA–SLEDAI assessment. Efficacy did not differ significantly between patients receiving RTX monotherapy and those receiving concomitant immunosuppressive agents (who had higher baseline disease activity). Articular, cutaneous, renal, and hematologic improvements were noted in 72%, 70%, 74%, and 88% of patients, respectively. Among responders, 41% experienced a relapse of disease, with a response in 91% after retreatment with RTX. Conclusion: Data from the AIR registry show a satisfactory tolerance profile and clinical efficacy of RTX in patients with SLE. The contrasting results with those from recent RCTs leave open the question of the therapeutic use of RTX in SLE. Additional controlled studies with new designs are needed to define the place of RTX in the therapeutic arsenal for SLE.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.27541

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 411

Metadata

Authors
Terrier, B., Amoura, Z., Ravaud, P., Hachulla, E., Jouenne, R., Combe, B., Bonnet, C., Cacoub, P., Cantagrel, A., De Bandt, M., Fain, O., Fautrel, B., Gaudin, P., Godeau, B., Harlé, J., Hot, A., Kahn, J., Lambotte, O., Larroche, C., Léone, J., Meyer, O., Pallot‐Prades, B., Pertuiset, E., Quartier, P., Schaerverbeke, T., Sibilia, J., Somogyi, A., Soubrier, M., Vignon, E., Bader‐Meunier, B., Mariette, X., & Gottenberg, J.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2010-08
Volume
62
Issue
8
Pages
2458-2466
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2089863875
Cited by
411
References
16
FWCI
30.31
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry. https://app.cochat.ai/papers/10.1002/art.27541
The paper
Terrier, B., Amoura, Z., Ravaud, P., Hachulla, E., Jouenne, R., Combe, B., Bonnet, C., Cacoub, P., Cantagrel, A., De Bandt, M., Fain, O., Fautrel, B., Gaudin, P., Godeau, B., Harlé, J., Hot, A., Kahn, J., Lambotte, O., Larroche, C., . . . Gottenberg, J. (2010). Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry. Arthritis & Rheumatism. https://doi.org/10.1002/art.27541

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.